D J Grierson1. 1. Department of Ophthalmology, Royal Infirmary, Glasgow, United Kingdom.
Abstract
OBJECTIVE: To review 10 years' data relating to visual screening of patients taking hydroxychloroquine. METHODS: Following baseline visual assessment, ophthalmic monitoring was carried out at six monthly intervals on 758 patients while on hydroxychloroquine. This consisted of corrected visual acuity, central field screening with a red Amsler grid, slit lamp examination, and retinoscopy. RESULTS: None of the patients suffered visual impairment from retinal toxicity, though 12 reported visual disturbance. This was related to ocular muscle imbalance in four. In the remainder, none of the ocular findings was directly attributable to hydroxychloroquine. Ten patients reported defects when tested with a red Amsler grid. None was related to retinal toxicity. Seven patients developed corneal drug deposits which cleared on stopping or reducing the dose of hydroxy-chloroquine. CONCLUSIONS: The findings support the view that following baseline ophthalmic examination for patients receiving hydroxychloroquine, regular ophthalmic screening is not required if the daily dose is less than 6.5 mg kg-1 and the cumulative dose is less than 200 g.
OBJECTIVE: To review 10 years' data relating to visual screening of patients taking hydroxychloroquine. METHODS: Following baseline visual assessment, ophthalmic monitoring was carried out at six monthly intervals on 758 patients while on hydroxychloroquine. This consisted of corrected visual acuity, central field screening with a red Amsler grid, slit lamp examination, and retinoscopy. RESULTS: None of the patients suffered visual impairment from retinal toxicity, though 12 reported visual disturbance. This was related to ocular muscle imbalance in four. In the remainder, none of the ocular findings was directly attributable to hydroxychloroquine. Ten patients reported defects when tested with a red Amsler grid. None was related to retinal toxicity. Seven patients developed corneal drug deposits which cleared on stopping or reducing the dose of hydroxy-chloroquine. CONCLUSIONS: The findings support the view that following baseline ophthalmic examination for patients receiving hydroxychloroquine, regular ophthalmic screening is not required if the daily dose is less than 6.5 mg kg-1 and the cumulative dose is less than 200 g.
Authors: Nathalie Costedoat-Chalumeau; Bertrand Dunogué; Gaëlle Leroux; Nathalie Morel; Moez Jallouli; Véronique Le Guern; Jean-Charles Piette; Antoine P Brézin; Ronald B Melles; Michael F Marmor Journal: Clin Rev Allergy Immunol Date: 2015-12 Impact factor: 8.667
Authors: Rodolfo Thomé; Adriel S Moraes; André Luis Bombeiro; Alessandro dos Santos Farias; Carolina Francelin; Thiago Alves da Costa; Rosária Di Gangi; Leonilda Maria Barbosa dos Santos; Alexandre Leite Rodrigues de Oliveira; Liana Verinaud Journal: PLoS One Date: 2013-06-14 Impact factor: 3.240